2023 BioInfect Conference
Alderley Park Conference Centre
Wednesday 1st February 2023
About
The global COVID-19 pandemic has highlighted the importance of infectious disease control and antimicrobial resistance is one of the biggest public health challenges of our time. With the WHO declaring AMR one of the top 10 global public health threats facing humanity and with 3.57 million deaths associated with resistant pathogens in 2019, it is imperative that we tackle this serious threat now.
We can’t do it alone: a collaborative approach is needed across all sectors. BioInfect will look at the critical issues relating to the challenges of new anti-infective development, the endemic problem of resistance, and the considerations for creating a truly global and effective response to antimicrobial resistance.
Antimicrobial resistance today
Antimicrobial resistance arises when the organisms that cause infection evolve ways to survive treatment. Once standard treatments are ineffective, it is easier for infections to persist and spread. These resistant organisms can be found in people, animals, food and the environment. The rise and spread of antimicrobial resistance are creating a new generation of ‘superbugs’ that cannot be treated with existing medicines.
Drug-resistant bacteria infect over 50m people worldwide killing over 700,000 people each year. Without effective antibiotics, even minor surgery and routine operations could become high-risk procedures if serious infections can’t be treated.
2022 Attendees
In 2022 we are welcoming delegates from Alderley Park, Bruntwood SciTech, INFEX Therapeutics Ltd, Evotec, SRG, ProLab Diagnostics, Biocair, Liverpool School of Tropical Medicine, Blueberry Therapeutics Ltd, Lancaster University, Bugworks, Keele University, Cresset, Medicines Discovery Catapult, Quay Pharma, Biocair, F2G Ltd, National Physical Laboratory, University of Manchester, University of Leeds, Aviva Investors, National Institute for Health and Clinical Excellence, BMG LABTECH Ltd, Perfectus Biomed, University of Sheffield, ProLab Diagnostics, ArrePath, Centauri Therapeutics, University of Liverpool, SEDA Pharmaceutical Development Services, MAST Group, Katalyzt Ltd., Illumina, Collaborative Drug Discovery CDD Vault, LightOx, PhenUtest Diagnostics, DSTL, WHP Engineering Ltd., 30 Technology, Phoenix Dx Ltd., Bouygues E&S, Source Bioscience, Safeguard Biosystems Holding, Appleyard Lees, Opillotech Ltd. and many more to follow.......